• Every dose printed on the panel
  • Prices shown per serving
  • Cautions printed on the page
  • 30-day money-back guarantee

Research review

Acidophilus or probiotics: what the research does and doesn't show

Acidophilus is a single named species within the broad probiotic category, and research on it is strain-specific — so the evidence doesn't support a blanket answer for "which is better."

By Electric Tiger Editorial

The evidence doesn't support treating "acidophilus" and "probiotics" as two things you choose between. Acidophilus is one named species inside the broad probiotic category, which spans hundreds of species across several genera. Asking which is "better" is like asking whether an apple is better than fruit — and the research that does exist is specific to individual strains, not to acidophilus or "probiotics" as a whole.

What the evidence doesn't support

It doesn't support ranking acidophilus above or below "probiotics" generally, because there's no trial that pits a named L. acidophilus strain against a different probiotic species for the same outcome, in the same people, at the same time. It also doesn't support assuming every acidophilus product behaves like every other one. A genomic comparison of sequenced probiotic Lactobacillus strains found that closely related strains can differ enough in their genes that a trait identified in one doesn't transfer to another — the paper's stated conclusion was that features found in one strain or species "cannot necessarily be applied to a related one." That's true within the acidophilus species itself, and it's just as true across the wider probiotic category: a finding for one named strain of one species says nothing about a different strain of a different species sold under the same "probiotic" label.

What the trials found

A 2016 randomized, double-blind, placebo-controlled crossover trial gave adults (18–75) with self-reported lactose intolerance a single daily capsule of the DDS-1 strain of L. acidophilus — 10 billion CFU, taken with food — for 4 weeks, versus placebo for 4 weeks, with a lactose challenge at the end of each period. Of the 22 people who completed both arms, the DDS-1 period reduced diarrhea, cramping, vomiting and overall symptom score versus placebo, with no adverse events reported. That's a result for one specific strain at one specific dose, not for acidophilus, or probiotics, in general.

A 2022 systematic review looked at the published evidence on probiotics and prebiotics for lactose intolerance and found only three eligible trials of single probiotic strains, covering 117 people combined — the DDS-1 trial was one of them; the other two tested different genera entirely. It rated the risk of bias a concern in all three trials and the overall certainty of the evidence low, and said the strains involved were too different from each other to pool into one combined estimate. In other words, even within this small set of "probiotic" trials, the strains couldn't be treated as interchangeable.

A 2011 double-blind, placebo-controlled trial gave 60 adults with non-constipation functional bowel disorders a two-strain combination — L. acidophilus NCFM and Bifidobacterium lactis Bi-07 — at 2×10¹¹ CFU/day for 8 weeks, and found improved bloating severity versus placebo. Because it combined two species, it can't tell you what the acidophilus half contributed on its own. A 2014 follow-up isolated NCFM alone in 20 women with mild-to-moderate abdominal pain, at 2×10¹⁰ CFU twice daily for 21 days, and found NCFM alone changed a pain-related receptor in colon tissue — but the authors stated the trial was too small to draw conclusions about whether it actually helped symptoms. A separate in-vitro model of the human colon tested the NCFM strain against C. difficile and found no statistically significant reduction. Across all four trials, each result belongs to one named strain and one outcome — none of them supports a general statement about "acidophilus" or "probiotics" as categories.

What was compared Result
Acidophilus vs. a different probiotic species, head-to-head, same outcome No trial found
L. acidophilus DDS-1 vs. placebo, lactose-intolerance symptoms Reduced symptoms (22 adults, 4 weeks)
L. acidophilus NCFM + B. lactis Bi-07 vs. placebo, bloating Reduced bloating (60 adults, 8 weeks) — two-strain combination
L. acidophilus NCFM alone vs. combination, abdominal pain Receptor change; symptom result inconclusive (20 women, underpowered)

Questions people ask

Is acidophilus the same as probiotics?

No. "Probiotic" is a broad category of live microorganisms — spanning genera like Lactobacillus, Bifidobacterium and Saccharomyces — taken for a health purpose. Acidophilus is one species within that category. Every acidophilus product is a probiotic, but most probiotics aren't acidophilus.

Is acidophilus a probiotic or a prebiotic?

A probiotic. Acidophilus is a live bacterium; a prebiotic is a non-living fiber or compound (like inulin) that feeds bacteria already in the gut. The two are different categories entirely.

Which is better, acidophilus or probiotics generally?

The evidence doesn't support answering that. No trial compares a named acidophilus strain against a different probiotic species for the same outcome, and the acidophilus trials that exist each tested one strain at one dose for one narrow outcome — not a general "probiotic effect" that could be ranked against anything else.

What's the difference between acidophilus and other probiotics like rhamnosus or reuteri?

They're different species with separate research records. L. rhamnosus and L. reuteri are studied in their own trials, at their own doses, for their own outcomes — a result for one doesn't apply to L. acidophilus, and vice versa, for the same genetic-strain-specificity reason described above.

Are all probiotics acidophilus?

No. Acidophilus is one specific species. A product labeled simply "probiotic" without naming acidophilus may contain entirely different species instead, or in addition.

When to talk to a doctor

Persistent or severe digestive symptoms are a reason to see a doctor, not to pick a probiotic species off a shelf and hope. Neither acidophilus nor "probiotics" generally is a treatment for a digestive or gynecological condition. If you're immunocompromised, critically ill, or have a central line or heart valve condition, ask a doctor before starting any probiotic — rare but serious infections have been linked to several Lactobacillus species, covered in full in acidophilus side effects and who should not take acidophilus.

Sources

  1. Functional genomics of probiotic Lactobacilli Journal of clinical gastroenterology · 2008 · PMID 18685516Closely related Lactobacillus strains differ enough genetically that a finding for one named strain can't be assumed to apply to a different strain, even within the same species.
  2. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial Nutrition journal · 2016 · PMID 27207411A small crossover trial found the DDS-1 strain of L. acidophilus, at 10 billion CFU a day for 4 weeks, reduced diarrhea, cramping and vomiting during a lactose challenge, with no adverse events.
  3. The use of probiotics and prebiotics can enable the ingestion of dairy products by lactose intolerant individuals Clinical nutrition (Edinburgh, Scotland) · 2022 · PMID 36308983A systematic review found only three human trials of single-strain probiotics for lactose intolerance, rated the evidence low-certainty, and could not pool the strains into one estimate.
  4. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study Journal of clinical gastroenterology · 2011 · PMID 21436726A two-strain combination of L. acidophilus NCFM and B. lactis Bi-07, at a combined 2x10^11 CFU/day for 8 weeks, reduced bloating versus placebo in adults with functional bowel disorders — but this tested two species together, not acidophilus alone.
  5. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study Alimentary pharmacology & therapeutics · 2014 · PMID 24853043A small human trial found the NCFM strain of L. acidophilus alone changed a pain-related receptor in colon tissue, but the trial was too small to say whether it actually improved symptoms.
  6. The effect of polydextrose and probiotic lactobacilli in a Clostridium difficile-infected human colonic model Microbial ecology in health and disease · 2015 · PMID 26468159In a lab model of the human colon, the NCFM strain of L. acidophilus did not significantly reduce C. difficile levels.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.